Safety and efficacy during long-term treatment with moclobemide

Area of Science:

• Psychiatry
• Clinical Pharmacology

Background:

• Long-term treatment efficacy and safety are crucial for managing chronic conditions.
• Understanding adverse events and treatment outcomes informs clinical practice.

Purpose of the Study:

• To evaluate the safety and efficacy of long-term treatment in a large patient cohort.
• To compare adverse events between long-term and short-term treatment durations.
• To assess the impact on depression scores and relapse rates.

Main Methods:

• Analysis of safety data (adverse events, vitals, labs) in 1,120 patients.
• Comparison of adverse events between long-term (n=1,120) and short-term (n=706) treatment groups.
• Efficacy assessment using Hamilton Depression Rating Scale (HAM-D) and Clinical Global Impression (CGI) in 485 patients.

Main Results:

• Most frequent adverse events were insomnia, headache, and dizziness, consistent between short-term and long-term treatment.
• Blood pressure and heart rate showed minimal, non-significant changes; weight remained stable.
• Significant reduction in HAM-D scores (25.05 to 7.88) observed within one year; relapse rates were 14.8% and 12.2% in subsequent six-month periods.

Conclusions:

• Long-term treatment is associated with a generally favorable safety profile.
• The treatment demonstrates sustained efficacy in reducing depression symptoms and managing relapses.
• Clinical monitoring of adverse events and efficacy is recommended for optimal patient outcomes.